Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

• Main Authors: Brandon J. Patterson (Author), Chi-Chang Chen (Author), Catherine B. McGuiness (Author), Lisa I. Glasser (Author), Kainan Sun (Author), Philip O. Buck (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 in the United States (US) for the prevention of herpes zoster in adults aged 50 years and older. The vaccine is administered in two doses, with the second dose administration recommended between two and six months after the firs...